Precision Biologics

23 articles about Precision Biologics

• Precision Biologics to Present at the American Association for Cancer Research (AACR) Annual Meeting on April 8th, 2024

  4/5/2024

  Precision Biologics, Inc. reports its lead monoclonal antibody, NEO-201, targets circulating human naïve regulatory T cells (Tregs) in both healthy donors and cancer patients.

• Precision Biologics to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 3rd, 2023

  11/2/2023

  Precision Biologics will deliver a poster presentation on preliminary results of the ongoing phase 2 trial, combining NEO-201 with pembrolizumab for the treatment of patients resistant to prior checkpoint inhibitor therapy at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting at the San Diego Convention Center in San Diego, CA on November 3rd, 2023.

• Precision Biologics Announces the United States Patent and Trademark Office (USPTO) has granted a Patent for its Lead Monoclonal Antibody, NEO-201, For the Treatment of Human Carcinomas

  10/2/2023

  Precision Biologics, Inc. ("Precision"), a clinical-stage immunotherapy and targeted oncology company, announced today that on September 26, 2023, the USPTO granted a patent for its lead clinical asset, NEO-201, which is currently being tested in Phase 2 human Clinical Trials in the US.

• Precision Biologics Announces Publication Of First-In-Human Phase 1 Clinical Trial With NEO-201

  4/3/2023

  Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announced today the publication of its first in human Phase I clinical trial with its novel monoclonal antibody, NEO-201, targeting the truncated core-1 O-glycan.

• Precision BioLogic's Chromogenic FIX Assay FDA-Cleared for Sale in U.S.

  1/5/2023

  Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510(k) clearance and the launch of its new CRYOcheck™ Chromogenic Factor IX assay in the U.S.

• Precision Biologics Successfully Completes Safety Phase and Begins Enrollment in Phase 2 Trial Combining NEO-201 and Pembrolizumab (Keytruda)

  12/14/2022

  Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announced today the successful completion of the safety phase and the enrollment of new patients into the expansion of the Phase 2 Clinical Trial Combining Precision Biologics NEO-201 monoclonal antibody with Pembrolizumab (Keytruda).

• Precision Biologics To Deliver Poster Presentations On Clinical And Scientific Programs At Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

  11/9/2022

  Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, will present at the SITC 37th Annual Meeting (2022) in Boston, MA.

• Precision BioLogic Launches New Product to Improve Testing for Hemophilia B

  5/9/2022

  Precision BioLogic Inc. a leading developer of hemostasis diagnostic products, is pleased to announce the launch of its new CRYO check  Chromogenic Factor IX assay in Canada, the European Union, Australia, and New Zealand.

• CRYOcheck™ Chromogenic Factor VIII Assay Cleared for Sale in U.S.

  7/20/2020

  Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510 clearance and the launch of its new CRYOcheck Chromogenic Factor VIII assay in the U.S.

• Precision BioLogic's CRYOcheck™ Factor VIII Inhibitor Kit Cleared for Sale in U.S.

  3/13/2019

  Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510 clearance and the launch of its CRYOcheck Factor VIII Inhibitor Kit in the U.S. This clearance follows approvals received from regulatory authorities in Canada, the European Union, Australia, and New Zealand, where the kit launched in February of this year.

• Precision BioLogic Acquires Affinity Biologicals

  11/1/2018

  This acquisition marks an important step in the development of Precision BioLogic and execution of their strategic plan.

• Working to Improve Hemophilia A Testing: Precision BioLogic presents new data at the 64th Annual SSC meeting

  7/19/2018

  Precision BioLogic unveiled data from a study using a new kit for a Modified Nijmegen-Bethesda Assay (MNBA) at the International Society on Thrombosis and Haemostasis' Scientific and Standardization Committee (SSC) meeting in Dublin.

• Precision BioLogic Presents New Approach to Standardize and Improve Inhibitor Testing for People with Hemophilia A

  3/13/2018

  New data highlights promising performance of a new kit for use in a modified Nijmegen-Bethesda Assay

• NantHealth's Biotech Mogul CEO Sued Over Capital Investment in Precision Biologics

  7/13/2017

• Precision Biologics, A Nantworks Company, To Present Combination Immunotherapy Of A Novel Neo-Epitope Antibody Targeting Ovarian And Uterine Cancer At The AACR Annual Meeting 2016

  4/18/2016

• Precision Biologics, A Nantworks Immunotherapy Company, Announces Cooperative Research And Development Agreement (CRADA) With The National Cancer Institute (NCI)

  12/21/2015

• Patrick Soon-Shiong's NantWorks Takes Stake in Precision Biologics with $50 Million Investment

  10/19/2015

• Precision Biologics Completes Patient Accrual To Its Ensituximab Phase II Colorectal Cancer Study

  5/20/2015

• EMD Millipore Announces Agreement With Precision Biologics To Provide Upstream Process Development Services

  2/2/2015

• Precision Biologics Release: NPC-1C Therapy Provides Hope For Patients With Metastatic Colorectal Cancer Showing Exciting Preliminary Results

  1/13/2015